New hope for lung cancer patients with brain tumors: drug duo enters trial
NCT ID NCT07197008
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs, Sacituzumab tirumotecan and bevacizumab, in 50 people with a specific type of lung cancer (EGFR-mutant nonsquamous NSCLC) that has spread to the brain and no longer responds to standard targeted therapy. The goal is to see if the combination can shrink brain tumors and slow disease progression. Participants receive the drugs by IV every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with EGFR-mutant lung cancer that has spread to the brain and stopped responding to standard therapy.
What could go wrong
This is a small, early-phase (Phase 2) single-arm study with no comparison group, so results may not be definitive. The combination may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••